JPH0733386B2 - キヌクリジン誘導体 - Google Patents

キヌクリジン誘導体

Info

Publication number
JPH0733386B2
JPH0733386B2 JP5500353A JP50035392A JPH0733386B2 JP H0733386 B2 JPH0733386 B2 JP H0733386B2 JP 5500353 A JP5500353 A JP 5500353A JP 50035392 A JP50035392 A JP 50035392A JP H0733386 B2 JPH0733386 B2 JP H0733386B2
Authority
JP
Japan
Prior art keywords
diseases
compound
substance
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP5500353A
Other languages
English (en)
Japanese (ja)
Other versions
JPH06504292A (ja
Inventor
文隆 伊藤
洋司 近藤
薫 嶋田
正己 中根
ロウ，ジヨン・アダムス・ザ・サード
ローセン，テリー・ジエイ
ヤング、ビングウエイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Original Assignee
PFIZER
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24845673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH0733386(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PFIZER filed Critical PFIZER
Publication of JPH06504292A publication Critical patent/JPH06504292A/ja
Publication of JPH0733386B2 publication Critical patent/JPH0733386B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP5500353A 1991-05-31 1992-04-28 キヌクリジン誘導体 Expired - Lifetime JPH0733386B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70840491A 1991-05-31 1991-05-31
US708,404 1991-05-31
PCT/US1992/003317 WO1992021677A1 (en) 1991-05-31 1992-04-28 bibNUCLIDINE DERIVATIVES

Publications (2)

Publication Number Publication Date
JPH06504292A JPH06504292A (ja) 1994-05-19
JPH0733386B2 true JPH0733386B2 (ja) 1995-04-12

Family

ID=24845673

Family Applications (2)

Application Number Title Priority Date Filing Date
JP5500353A Expired - Lifetime JPH0733386B2 (ja) 1991-05-31 1992-04-28 キヌクリジン誘導体
JP6241456A Expired - Lifetime JP2645225B2 (ja) 1991-05-31 1994-10-05 キヌクリジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP6241456A Expired - Lifetime JP2645225B2 (ja) 1991-05-31 1994-10-05 キヌクリジン誘導体

Country Status (41)

Country Link
US (3) US5807867A (https=)
EP (1) EP0587723B1 (https=)
JP (2) JPH0733386B2 (https=)
KR (1) KR100214905B1 (https=)
CN (1) CN1048492C (https=)
AP (1) AP299A (https=)
AT (1) ATE135006T1 (https=)
AU (1) AU657552B2 (https=)
BG (1) BG61694B1 (https=)
BR (1) BR9206073A (https=)
CA (1) CA2102179C (https=)
CZ (1) CZ281403B6 (https=)
DE (4) DE9290063U1 (https=)
DK (1) DK0587723T3 (https=)
EG (1) EG19944A (https=)
ES (1) ES2084361T3 (https=)
FI (1) FI114475B (https=)
GR (1) GR3019687T3 (https=)
GT (1) GT199200028A (https=)
HU (1) HU217548B (https=)
IE (1) IE72473B1 (https=)
IL (1) IL102008A (https=)
IS (1) IS1611B (https=)
LU (1) LU91293I2 (https=)
MA (1) MA22539A1 (https=)
MX (1) MX9202554A (https=)
NL (1) NL300250I2 (https=)
NO (2) NO302701B1 (https=)
NZ (2) NZ270673A (https=)
OA (1) OA09867A (https=)
PL (1) PL171379B1 (https=)
PT (1) PT100546B (https=)
RO (1) RO110499B1 (https=)
RU (1) RU2103269C1 (https=)
SK (1) SK278788B6 (https=)
TW (1) TW204349B (https=)
UA (1) UA27776C2 (https=)
UY (1) UY23422A1 (https=)
WO (1) WO1992021677A1 (https=)
YU (1) YU48995B (https=)
ZA (1) ZA923942B (https=)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU657552B2 (en) * 1991-05-31 1995-03-16 Pfizer Inc. Quinuclidine as substance P antagonists
DE69213451T2 (de) * 1991-06-20 1997-01-09 Pfizer Inc., New York Fluoralkoxybenzylaminoderivate stickstoffhaltiger heterocyclen
WO1994004496A1 (en) * 1992-08-19 1994-03-03 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
CA2149242C (en) * 1992-11-12 1998-08-04 Fumitaka Ito Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
JP2822274B2 (ja) * 1993-05-19 1998-11-11 ファイザー製薬株式会社 Ｐ物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0659409A3 (en) * 1993-11-23 1995-08-09 Pfizer Substance P antagonists to inhibit angiogenesis.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
NZ329807A (en) * 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
AR018772A1 (es) * 1998-03-19 2001-12-12 Takeda Chemical Industries Ltd Composicion farmaceutica para prevenir o tratar depresion, inquietud, enfermedad maniaca depresiva o psicopatia, compuesto heterociclico comprendido en lamisma, prodroga obtenida a partir del anterior, metodo para producir dicho compuesto y su uso
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
MXPA02004330A (es) 1999-11-03 2004-07-30 Albany Molecular Res Inc Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
KR100821410B1 (ko) 2000-07-11 2008-04-10 에이엠알 테크놀로지, 인크. 4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
PL367944A1 (en) * 2001-07-20 2005-03-07 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
US6686507B2 (en) 2002-03-06 2004-02-03 Pfizer Inc Purification of 2-methoxy-5-trifluoromethoxybenzaldehyde
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
NZ569331A (en) * 2003-01-21 2010-08-27 Yeda Res & Dev COP 1 for treatment of inflammatory bowel diseases
WO2005045395A2 (en) * 2003-10-27 2005-05-19 Meyer Donald W Method of detecting bovine spongiform encephalopathy
ATE473967T1 (de) * 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
CA2554823A1 (en) 2004-01-30 2005-09-09 Pfizer Products Inc. Nk-1 receptor antagonists to improve anesthesia recovery
LT1713504T (lt) * 2004-01-30 2017-09-11 Zoetis Services Llc Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms
SI1713801T1 (sl) 2004-02-02 2008-04-30 Pfizer Prod Inc Postopek priprave 1-(2S,3S)-2-benzhidril-N-(5-terc-butil-2-metoksibenzil)kinuklidin-3- amina
UA91341C2 (ru) 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
UA95454C2 (uk) 2005-07-15 2011-08-10 Амр Текнолоджи, Інк. Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
JP5489333B2 (ja) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション 脂肪酸合成阻害剤を用いた治療の方法
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh) 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
AU2010247763B2 (en) 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
ME02925B (me) 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法
CN121221782A (zh) 2017-06-30 2025-12-30 傲拓神经科学公司 用于治疗抑郁的nk-1拮抗剂组合物和方法
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
CN111918647A (zh) 2018-02-26 2020-11-10 圣拉斐尔医院有限公司 用于治疗眼痛的nk-1拮抗剂
KR102102109B1 (ko) * 2018-07-10 2020-04-20 성균관대학교산학협력단 N-벤즈히드릴 퀴뉴클리딘 유도체를 포함하는 나트륨 누출 채널 억제용 조성물
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033288A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2021180885A1 (en) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency
AT527172A1 (de) 2023-04-25 2024-11-15 Vetviva Richter Gmbh Maropitantformulierung

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
DE69105131T2 (de) * 1990-06-01 1995-03-23 Pfizer 3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
DE4026743A1 (de) * 1990-08-24 1992-02-27 Teves Gmbh Alfred Blockiergeschuetzte bremsanlage fuer kraftfahrzeuge
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
AU657552B2 (en) * 1991-05-31 1995-03-16 Pfizer Inc. Quinuclidine as substance P antagonists
EP1082959A1 (en) * 1991-09-20 2001-03-14 Glaxo Group Limited NK1 Antagonists for the treatment of depression
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
US5990125A (en) * 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer
EP0785198B1 (de) * 1996-01-19 2000-07-05 Lonza Ag Verfahren zur Herstellung von optisch aktivem 3-Chinuclidinol

Also Published As

Publication number Publication date
BG61694B1 (bg) 1998-03-31
FI935297A0 (fi) 1993-11-29
DE122006000066I2 (de) 2007-12-06
IE72473B1 (en) 1997-04-23
BR9206073A (pt) 1994-12-06
EP0587723A1 (en) 1994-03-23
NZ270673A (en) 1997-07-27
NO934312L (no) 1993-11-29
UY23422A1 (es) 1992-11-12
FI114475B (fi) 2004-10-29
PT100546B (pt) 1999-12-31
CZ281403B6 (cs) 1996-09-11
SK390692A3 (en) 1998-02-04
EP0587723B1 (en) 1996-03-06
KR100214905B1 (ko) 1999-08-02
NO934312D0 (no) 1993-11-29
HU9303393D0 (en) 1994-03-28
IE921729A1 (en) 1992-12-02
NZ242956A (en) 1995-06-27
AU1990192A (en) 1993-01-08
IL102008A (en) 1995-12-08
GT199200028A (es) 1993-11-20
NO2007003I1 (no) 2007-03-26
JPH07285965A (ja) 1995-10-31
US6222038B1 (en) 2001-04-24
DK0587723T3 (da) 1996-04-01
ES2084361T3 (es) 1996-05-01
DE69208877D1 (de) 1996-04-11
IS3871A (is) 1992-12-02
PL171379B1 (en) 1997-04-30
ATE135006T1 (de) 1996-03-15
YU56492A (sh) 1995-03-27
RU2103269C1 (ru) 1998-01-27
EG19944A (en) 1997-02-27
IL102008A0 (en) 1992-12-30
AU657552B2 (en) 1995-03-16
YU48995B (sh) 2003-04-30
WO1992021677A1 (en) 1992-12-10
IS1611B (is) 1996-10-18
US5939433A (en) 1999-08-17
RO110499B1 (ro) 1996-01-30
CZ390692A3 (en) 1994-02-16
DE122006000066I1 (de) 2007-03-22
JPH06504292A (ja) 1994-05-19
CA2102179C (en) 1998-10-27
HU217548B (hu) 2000-02-28
LU91293I2 (fr) 2007-02-06
OA09867A (en) 1994-08-15
DE9290063U1 (de) 1994-02-24
NL300250I2 (nl) 2007-03-01
TW204349B (https=) 1993-04-21
AP299A (en) 1994-01-14
ZA923942B (en) 1993-11-29
HUT70151A (en) 1995-09-28
MA22539A1 (fr) 1992-12-31
CN1048492C (zh) 2000-01-19
CA2102179A1 (en) 1992-12-01
US5807867A (en) 1998-09-15
GR3019687T3 (en) 1996-07-31
CN1067428A (zh) 1992-12-30
JP2645225B2 (ja) 1997-08-25
SK278788B6 (sk) 1998-02-04
NL300250I1 (nl) 2007-02-01
DE69208877T2 (de) 1996-07-25
AP9200384A0 (en) 1992-07-31
BG98248A (bg) 1994-07-29
PT100546A (pt) 1993-08-31
UA27776C2 (uk) 2000-10-16
NO302701B1 (no) 1998-04-14
NO2007003I2 (no) 2011-04-18
FI935297L (fi) 1993-11-29
MX9202554A (es) 1992-11-01

Similar Documents

Publication Publication Date Title
JP2645225B2 (ja) キヌクリジン誘導体
US5886009A (en) Quinuclidine derivative as a substance P antagonist
JP2656699B2 (ja) 置換ベンジルアミノキヌクリジン
JP2757234B2 (ja) Ｐ物質拮抗薬としての架橋アザ二環式誘導体
US5688804A (en) 3-Benzylamino-2-phenyl-piperidine derivatives as substance P receptor antagonists
JPH06506473A (ja) 窒素含有複素環化合物のフルオロアルコキシベンジルアミノ誘導体
IL100584A (en) 1-alkyl-2-benzhydryl-3-arylmethylamino quinuclidinium salts and pharmaceutical compositions containing them
EP0840735A1 (en) Resolution of 1-azabicyclo 2.2.2]octan-3-amine, 2-(diphenylmethyl)-n- 2-methoxy-5-(1-methylethyl)phenyl]methyl]
HK1000246B (en) Quinuclidine derivative as substance p antagonist
HK1000246A1 (en) Quinuclidine derivative as substance p antagonist